Replimune Shares Tumble 56% After FDA Rejects Melanoma Drug RP1

Replimune shares extended their losses, plummeting 56% after the U.S. Food and Drug Administration (FDA) rejected its melanoma drug, RP1. This decision led to a significant market reaction for the biotechnology company.